International Stem Cell CORP (ISCO) stock
ISCOOTCPharmaceutical PreparationsFiscal year ends December 31
$0.28+0.00 (+0.89%)
Close on Oct 19, 2026Market cap $2.27MP/E –Yield –
International Stem Cell free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
International Stem Cell's free cash flow for the twelve months ending Jun 30, 2026 was $333.00K, up 851.4% year over year. For fiscal 2025 it was -$35.00K. The highest annual figure on record is $849.00K in fiscal 2023.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$35.00K | – |
| FY2024 | Dec 31, 2024 | -$153.00K | -118.0% |
| FY2023 | Dec 31, 2023 | $849.00K | +156.5% |
| FY2022 | Dec 31, 2022 | $331.00K | – |
| FY2021 | Dec 31, 2021 | -$1.32M | – |
| FY2020 | Dec 31, 2020 | -$369.00K | – |
| FY2019 | Dec 31, 2019 | -$1.56M | – |
| FY2018 | Dec 31, 2018 | -$1.27M | – |
| FY2017 | Dec 31, 2017 | -$2.25M | – |
| FY2016 | Dec 31, 2016 | -$4.43M | – |
| FY2015 | Dec 31, 2015 | -$4.16M | – |
| FY2014 | Dec 31, 2014 | -$6.71M | – |
| FY2013 | Dec 31, 2013 | -$5.81M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $160.00K | – |
| Q1 FY2026 | Mar 31, 2026 | $98.00K | -55.9% |
| Q4 FY2025 | Dec 31, 2025 | $29.00K | – |
| Q3 FY2025 | Sep 30, 2025 | $46.00K | -79.1% |
| Q2 FY2025 | Jun 30, 2025 | -$332.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $222.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$75.00K | -146.6% |
| Q3 FY2024 | Sep 30, 2024 | $220.00K | +358.3% |
| Q2 FY2024 | Jun 30, 2024 | -$97.00K | -122.1% |
| Q1 FY2024 | Mar 31, 2024 | -$201.00K | -200.0% |
| Q4 FY2023 | Dec 31, 2023 | $161.00K | +103.8% |
| Q3 FY2023 | Sep 30, 2023 | $48.00K | -42.9% |
| Q2 FY2023 | Jun 30, 2023 | $439.00K | – |
| Q1 FY2023 | Mar 31, 2023 | $201.00K | – |
| Q4 FY2022 | Dec 31, 2022 | $79.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $84.00K | -67.9% |
| Q4 FY2020 | Dec 31, 2020 | -$315.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$279.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$37.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $262.00K | – |
| Q4 FY2019 | Dec 31, 2019 | -$399.00K | -6750.0% |
| Q3 FY2019 | Sep 30, 2019 | -$60.00K | – |
| Q2 FY2019 | Jun 30, 2019 | -$703.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$399.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $6.00K | – |
| Q3 FY2018 | Sep 30, 2018 | -$566.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$602.00K | – |
| Q1 FY2018 | Mar 31, 2018 | -$105.00K | – |
| Q4 FY2017 | Dec 31, 2017 | -$516.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$348.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$811.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$579.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$976.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$457.00K | – |
| Q2 FY2016 | Jun 30, 2016 | -$965.00K | – |
See a number that looks wrong?